OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受体激动剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关副作用是常见，但严重到足以停药程度是罕见。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似巴胺巴胺激动剂，与第一代巴胺激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与巴胺D2受体有较高结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受体激动剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴胺的多巴胺激动剂，与第一代多巴胺激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴激动剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴的多巴激动剂，与第一代多巴激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴D2有较高的结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受激剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴胺的多巴胺激剂，与第一代多巴胺激剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受有较高的结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受体动剂临床应。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促腺素释放因子治相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴胺的多巴胺动剂，与第一代多巴胺动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受体激动临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期性腺激素释放疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴胺的多巴胺激动，与第一代多巴胺激动不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受体激动剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴胺的多巴胺激动剂，与第一代多巴胺激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评受体激动剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关副作用是常见，但严重到足以停药程度是罕见。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多多激动剂，与第一代多激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多D2受体有较高结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价受体激动剂临床应疗效性。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似的激动剂，与第一代激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明与D2受体有较高的结合力。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴胺受体激动剂临床应疗效。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促腺激素释放因子治疗相关副作用是常见，但严重到足以停药程度是罕见。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴胺多巴胺激动剂，与第一代多巴胺激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多巴胺D2受体有较高结合力。